Boston Common Asset Management’s AstraZeneca AZN Stock Holding History

Boston Common Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.1M	Sell	37,467 -3,493	-9%	-$657K	0.42%	69
2026 Q1	$8.08M	Sell	40,960 -752	-2%	-$145K	0.52%	61
2025 Q4	$7.67M	Sell	41,712 -89,007	-68%	-$15.6M	0.46%	63
2025 Q3	$34.3M	Buy	130,719 +4,830	+4%	+$731K	0.96%	21
2025 Q2	$30.1M	Sell	125,889 -2,935	-2%	-$411K	0.85%	29
2025 Q1	$32.3M	Sell	128,824 -7,119	-5%	-$1.03M	0.98%	15
2024 Q4	$31.9M	Sell	135,943 -26,676	-16%	-$3.73M	0.93%	20
2024 Q3	$45.7M	Sell	162,619 -14,890	-8%	-$2.4M	1.19%	10
2024 Q2	$50.3M	Sell	177,509 -6,684	-4%	-$1.01M	1.29%	8
2024 Q1	$45.1M	Sell	184,193 -75	-0%	-$9.93K	1.08%	17
2023 Q4	$45.1M	Sell	184,268 -7,420	-4%	-$965K	1.03%	18
2023 Q3	$47M	Sell	191,688 -2,734	-1%	-$373K	1.12%	11
2023 Q2	$50.3M	Buy	194,422 +22,005	+13%	+$3.24M	1.07%	13
2023 Q1	$42.8M	Buy	172,417 +139,221	+419%	+$18.7M	0.89%	27
2022 Q4	$4.5M	Buy	33,196 +6,685	+25%	+$838K	0.22%	110
2022 Q3	$2.91M	Buy	26,511 +7,182	+37%	+$911K	0.15%	134
2022 Q2	$2.55M	Buy	+19,329	New	+$2.54M	0.13%	145

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boston Common Asset Management's AZN Position: Q2 2026 in Review

Boston Common Asset Management reduced its AstraZeneca (AZN) stake by 8.5% in Q2 2026, selling an estimated $657K and leaving 37,467 shares worth $7.1M. The position accounts for 0.42% of the portfolio, ranked #69.

Boston Common Asset Management first reported a position in AZN in Q2 2022 and has held it in 17 quarters since. The position peaked at $50.3M in Q2 2023. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Boston Common Asset Management held 37,467 shares of AstraZeneca worth $7.1M as of Q2 2026.
Boston Common Asset Management sold 3,493 AstraZeneca shares in Q2 2026, an estimated $657K.
AstraZeneca made up 0.42% of Boston Common Asset Management's portfolio in Q2 2026, its #69 holding.
Boston Common Asset Management first reported a position in AstraZeneca in Q2 2022 and has held it in 17 quarters since.
Boston Common Asset Management's AstraZeneca position peaked at $50.3M in Q2 2023.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Boston Common Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.